We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Influence of Thyroid Hormones on the Woundhealing Process

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified June 2009 by Hannover Medical School.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT00929318
First Posted: June 29, 2009
Last Update Posted: June 29, 2009
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Genzyme, a Sanofi Company
Information provided by:
Hannover Medical School
June 26, 2009
June 29, 2009
June 29, 2009
June 2009
December 2009   (Final data collection date for primary outcome measure)
Evidence for different cytokine levels in euthyroid vs hypothyroid condition confirmed by bood serum samples [ Time Frame: 21 days after surgery ]
Same as current
No Changes Posted
Differences in duration and clinical characteristics of the wound healing process verified by a modified ASEPSIS score. [ Time Frame: 21 days after surgery ]
Same as current
Not Provided
Not Provided
 
Influence of Thyroid Hormones on the Woundhealing Process
Clinical Investigations on Cytokin-Gradients in Hypo/Euthyroid Patients. Evaluation of Expression of Different Pro-and Anti-Inflammatory Cyto-/Chemokines in Skin Wounds After Surgery of Benign Goitres (Struma Multinodosa) or Malignant Diseases of Thyroid Gland (Papillary Thyroid Carcinoma) in Correlation to the Status of Wound Healing of the Neck Wound
Main goal of this clinical investigation is to investigate different cytokines in wound fluids of euthyroid vs. hypothyroid patients. As a primary endpoint we want to evaluate if different cytokine levels in euthyroid vs. hypothyroid patients exist and to what extent these cytokines differ. Our targeted cytokines are: IL6, IL10, TNFa and MCP-1. From the literature these 4 factors seem to be the most reasonable to measure and to focus on. Additionally we focus on these 4 factors for financial reasons, technically there wouldn't be a problem to measure more, which is correlated with higher costs. Besides, more than 6 factors would mean larger amounts of sample fluids needed, which would cause technical problems. These factors don`t have to change in the same direction. Secondarily, we believe that differences in cytokine profiles of hypothyroidism vs. euthyroidism will correlate to differences in duration and clinical characteristics of the wound healing process.
Not Provided
Interventional
Not Provided
Allocation: Randomized
Masking: None (Open Label)
Primary Purpose: Basic Science
  • Thyroid Neoplasms
  • Thyroid Carcinoma
Procedure: blood sampling
  • Active Comparator: benign
    patients after surgery because of a benign disease
    Interventions:
    • Procedure: blood sampling
    • Procedure: blood sampling
  • Active Comparator: DTC
    Patients after thyroidectomy because of papillary carcinoma of the thyroid gland
    Intervention: Procedure: blood sampling
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
26
April 2010
December 2009   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Near total or total thyroidectomy because of struma multinodsa (nodular goiter) with or without substitution of thyroid hormone after operation
  • Total thyroidectomy because of papillary carcinoma of thyroid gland (T1/T2 carcinoma, N1, M0) with planned radio-ablative therapy (RAT) without or with rhTSH

Exclusion Criteria:

  • Pat< 18 years
  • Immune disease of thyroid gland (Graves disease)
  • Severe immunodeficiency
  • Immunosuppressive medication because of solid Organ transplantation
  • Hepatitis A/B/C or HIV
  • All exclusion criteria for any surgical procedure
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Germany
 
 
NCT00929318
MHH-THY-WH-09
No
Not Provided
Not Provided
Prof. Dr Georg FW Scheumann, Medizinische Hochschule Hannover
Hannover Medical School
Genzyme, a Sanofi Company
Not Provided
Hannover Medical School
June 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP